<p>ROC curves of %fPSA and PSA in predicting any prostate cancer for patients aged (A) 50–59 years; (B) 60–69 years; (C) 70–79 years; and (D) 80–89 years with a PSA level of 4.0–10.0 ng/ml.</p
Abstract Purpose This study aims to establish and validate a new diagnosis model called P.Z.A. score...
To study the correlations between the clinical examinations and latent prostate cancer in old males ...
To reduce the number of unnecessary biopsies in patients with benign prostatic disease, however, wit...
<p>ROC curves of %fPSA and PSA in predicting high-grade prostate cancer for patients aged (A) 50–59 ...
<p>ROC curve for the age group 60–69 years stratified for fPSA values ≤18% vs. >18% and ≤21% vs. >21...
<p>ROC curve for the age group ≥ 70 years stratified for fPSA values ≤18% vs. >18% and ≤21% vs. >21%...
<p>ROC curve for the age group ≤50–59 years stratified for fPSA values ≤18% vs. >18% and ≤21% vs. >2...
<p>(a)All study population: AUC-tPSA vs. AUC-%fPSA (P<0.001), AUC-PSAD vs. AUC-tPSA(P = 0.05), AUC-m...
Early diagnosis of disease has potential to reduce morbidity and mortality. Biomarkers may be useful...
<p>(a)All study population: AUC-tPSA vs. AUC-%fPSA (P<0.001), AUC-PSAD vs. AUC-tPSA(P>0.05), AUC-mod...
<p>Receiver operating characteristic (ROC) curves for risk prediction of prostate cancer for three d...
<p>Serum PSA is compared to the added value of serum (A) homocysteine, (B) cystathionine, and (C) cy...
<p>(a)All study population: AUC-tPSA vs. AUC-%fPSA (P<0.001), AUC-PSAD vs. AUC-tPSA(P<0.001), AUC-mo...
<p>Area under the curve (AUC) comparing measured PSA, genetically corrected PSA risk score based on ...
The white contour lines indicates the rates 0.1, 0.2 and 0.3. The modelled values are based on data ...
Abstract Purpose This study aims to establish and validate a new diagnosis model called P.Z.A. score...
To study the correlations between the clinical examinations and latent prostate cancer in old males ...
To reduce the number of unnecessary biopsies in patients with benign prostatic disease, however, wit...
<p>ROC curves of %fPSA and PSA in predicting high-grade prostate cancer for patients aged (A) 50–59 ...
<p>ROC curve for the age group 60–69 years stratified for fPSA values ≤18% vs. >18% and ≤21% vs. >21...
<p>ROC curve for the age group ≥ 70 years stratified for fPSA values ≤18% vs. >18% and ≤21% vs. >21%...
<p>ROC curve for the age group ≤50–59 years stratified for fPSA values ≤18% vs. >18% and ≤21% vs. >2...
<p>(a)All study population: AUC-tPSA vs. AUC-%fPSA (P<0.001), AUC-PSAD vs. AUC-tPSA(P = 0.05), AUC-m...
Early diagnosis of disease has potential to reduce morbidity and mortality. Biomarkers may be useful...
<p>(a)All study population: AUC-tPSA vs. AUC-%fPSA (P<0.001), AUC-PSAD vs. AUC-tPSA(P>0.05), AUC-mod...
<p>Receiver operating characteristic (ROC) curves for risk prediction of prostate cancer for three d...
<p>Serum PSA is compared to the added value of serum (A) homocysteine, (B) cystathionine, and (C) cy...
<p>(a)All study population: AUC-tPSA vs. AUC-%fPSA (P<0.001), AUC-PSAD vs. AUC-tPSA(P<0.001), AUC-mo...
<p>Area under the curve (AUC) comparing measured PSA, genetically corrected PSA risk score based on ...
The white contour lines indicates the rates 0.1, 0.2 and 0.3. The modelled values are based on data ...
Abstract Purpose This study aims to establish and validate a new diagnosis model called P.Z.A. score...
To study the correlations between the clinical examinations and latent prostate cancer in old males ...
To reduce the number of unnecessary biopsies in patients with benign prostatic disease, however, wit...